Anorexia Nervosa, Parkinson Disease
Conditions
Keywords
Emotional intelligence, Cognition, Emotional valence, Anorexia nervosa, Parkinson's disease
Brief summary
The main aim of this study is to demonstrate how disorders characterized by different types of inflexibility, cognitive-affective type for Anorexia nervosa and motor one for Parkinson's disease, have an impact on how emotional stimuli are processed and on the transition within emotional states.
Detailed description
Although many psychometric models have been developed on emotions, affect measurements, which represent the measurement of behavioural, subjective and neuropsychophysiological changes associated with an emotional episode, still remains one of the most debated topics. Emotions are entities with blurred boundaries and with substantial idiosyncrasies that characterize their measurable manifestations. One of the most consolidated theoretical reference models for measuring affect is that of James Russel called the Affective Core Model. According to this model, emotion arises when the undifferentiated and pre-reflective magma of affect (core affect) is attracted by an external (or internal) object that can be defined as emotigenic, i.e. capable of defining the nature of emotional experience by orienting it along two dimensions principal factors. The most used theoretical model for affect measurement is the one that describes an emotional episode in the light of two distinguishable continuous dimensions: that of hedonic value (identifies the degree of pleasantness of the emotional event), of a subjective nature, and that of arousal or psychophysiological activation. Although this model has been widely corroborated in various disciplines, there is still a lack of a clear description of the process that allows an individual to transition from one emotionally object-oriented state to another. This project proposes and intends to validate a new modality of three-dimensional psychometric modeling of emotions, based on the intersection between the consolidated two-dimensional model of arousal-valence and a third purely cognitive component definable as mental flexibility, capable of including high-level cognitive processes, intrinsically connected with the emotional sphere, such as emotional intelligence (Emotional Intelligence, EI) and emotional regulation.
Interventions
Colored Progressive Matrices (BDM), Stroop Test (Caffarra et al., 2000), Stroop Test (Caffarra et al., 2000), Attentional Matrices (part I - Della Sala et al., 1992), Attentional Matrices (part The - Della Sala et al., 1992), Trail Making Test (Giovagnoli et al., 1996 - part A), Trail Making Test (Giovagnoli et al., 1996 - part B), Trail Making Test (Giovagnoli et al., 1996 - B-A), MMSE (Grigoletto et al., 1999), Clock Drawing - PD (Caffarra et al., 2011), Digit Span Forward (Orsini et al., 1987), Digit Span Backward (Monaco et al. , 2012), 15 Rey Words - Immediate Recall (BDM), 15 Rey Words - Deferred Recall (BDM), Phonemic Fluency (Costa et al., 2014), Semantic Fluency (Costa et al., 2014), Frontal Assessment Battery ( FAB - Apollonio et al.,2005).
STAI Y2 (trait anxiety), TEIque (153 items), STAI Y1 (state anxiety), ERQ (10 items), EISR (33 items), BDI (21 items), WLEIS (16 ITEMS), CFI (20 ITEMS ), CCFQ (18 ITEM).
Subsequently, at both T0 and T1, standardized emotional images from the International Affective Picture System (IAPS) will be administered. The images will be chosen based on the arousal-valence parameters, eliminating those with stimuli that are too salient with respect to the disorders examined. The order of administration will be organized and randomized between subjects as follows: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each. For the entire duration of the test, peripheral physiological parameters such as ECG, BVP, GSR, EOG, RSP and facial EMG (corrugator and zygomaticus) will also be detected, as objective measures of emotional arousal (T0-T1).
Verbal Fluencies, Tower of London, TMT-A & B
STAI Y2 (20 items trait anxiety), TEIque (153 items), STAI Y1 (20 items state anxiety), DFlex (24 items), ERQ (10 items), EISR (33 items), BDI (21 items), TAS-20 (20 items), WLEIS (16 ITEMS), CFI (20 ITEMS), CCFQ (18 items).
the analysis of bio-humoral parameters (interleukin 6, cortisol, serotonin, catecholamines and endorphins) will be also performed through morning venous blood sampling at T0, at half of the rehabilitation process and at T1
Sponsors
Study design
Eligibility
Inclusion criteria
* Parkinson's Disease * Anorexia nervosa * Written informed consent
Exclusion criteria
* Other psychiatric disorders * Acute infectious diseases * Chronic inflammatory diseases * Other Disorders of central nervous system * Pregnancy or breastfeeding * tachy or bradyarrhythmias, other cardiac rhythm alterations that compromise the study of heart rate variability
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in International Affective Picture System (IAPS) | At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN) | Self-Assessment Manikin (SAM) scale. Range score for each image: 1-5 (IAPS test: 24 blocks of 2 minutes and for each block there will be 12 images of 10 seconds each). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in self-report questionnaires - STAI | At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN) | State-Trait Anxiety Inventory (STAI); score range 20-80 |
| Change in self-report questionnaires - BDI | At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN) | Beck's Depression Inventory (BDI); score range 0-63 |
| Change in Heart rate variability | At baseline T0 (hospital admission) and T1 (15 days after T0 for PD, 4 weeks after T0 for AN) | High frequency (range 0.15-0.40 hz) * Low frequency (range 00.4-0.15 hz) * Ratio Low frequency/High frequency |
| Change in analysis of bio-humoral parameters | At baseline T0 (hospital admission), after 2 weeks and T1 (4 weeks after T0 for AN) | Serotonin in serum (range 30 - 200 ng/ml) |
Countries
Italy